Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 13:30 save search
Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis
Published: 2022-03-23 (Crawled : 13:30) - biospace.com/
RANI | $6.625 -0.68% -0.68% 91K
|
|
| O: -1.29%
H: 6.06%
C: 3.07%
rt-102 therapeutics osteoporosis phase 1 phase 3
Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
Published: 2022-03-22 (Crawled : 13:30) - biospace.com/
PALI | $5.91 19.88% 16.58% 23M
|
Manufacturing
|
| O: 65.84%
H: 14.61%
C: -21.35%
lb1148 fda trial phase 3
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Published: 2022-03-10 (Crawled : 13:30) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment pos migraine positive phase 3
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
EVAX | $4.08 -2.63% -2.7% 25K
|
Manufacturing
|
| O: -0.7%
H: 8.77%
C: -2.81%
evx-02 trial phase 1 biotech iot phase 2 phase 3
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
OPTN | $0.9709 -5.74% -6.09% 670K
|
Health Services
|
| O: -3.89%
H: 0.0%
C: 0.0%
pos trial report positive results phase 3 topline
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
Published: 2022-03-02 (Crawled : 13:30) - globenewswire.com
PYPD | $4.425 4.44% 910
|
Health Technology
|
| O: 3.28%
H: 12.42%
C: 10.47%
trial phase 3 enroll
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-23 (Crawled : 13:30) - biospace.com/
CYTK | $65.56 -1.1% -1.11% 1.3M
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -6.95%
cardio trial star phase 3
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Published: 2022-02-22 (Crawled : 13:30) - biospace.com/
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: -2.39%
H: 6.28%
C: 1.9%
respiratory trial vaccine phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
TGTX | $14.25 1.06% 1.05% 3.2M
|
Health Technology
|
| O: 2.51%
H: 8.21%
C: 6.84%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
Published: 2022-02-03 (Crawled : 13:30) - biospace.com/
CYTH | $1.26 7.94% 33K
|
Professional, Scientific, and T...
|
| O: -1.35%
H: 2.74%
C: -5.48%
trappsol ema program therapeutics disease phase 3
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Published: 2022-01-25 (Crawled : 13:30) - achievelifesciences.com
ACHV | $4.47 1.36% 1.34% 52K
|
Health Technology
|
| O: -0.99%
H: 4.56%
C: 1.78%
trial life science phase 3
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
Published: 2022-01-20 (Crawled : 13:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.31%
H: 1.4%
C: 0.02%
ynote-775 keytruda trial results phase 3
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
VERA | $39.46 0.84% 0.84% 1.2M
|
Professional, Scientific, and T...
|
| O: -8.03%
H: 8.58%
C: 2.84%
fda trial therapeutics positive phase 3 lupus
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
Published: 2022-01-12 (Crawled : 13:30) - biospace.com/
CYT | $3.02 2.65% 1M
|
Manufacturing
|
| O: -8.58%
H: 3.39%
C: -6.0%
phase 1 trial phase 2 phase 3
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published: 2022-01-12 (Crawled : 13:30) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 1.71%
H: 1.17%
C: -3.83%
phase 3 syndros treatment
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
NBIO | $0.0898 15.32% 190K
|
|
| O: 0.17%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3 cancer train
Galmed announces positive results of Phase 1 study of Amilo-5MER
Published: 2022-01-10 (Crawled : 13:30) - biospace.com/
GLMD | $0.3641 -0.41% 65K
|
Health Technology
|
| O: -12.89%
H: 0.0%
C: 0.0%
phase 1 phase 2 positive phase 3
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
Published: 2022-01-05 (Crawled : 13:30) - biospace.com/
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
xywav positive phase 3 lancet sodium oxybate
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
Published: 2021-12-28 (Crawled : 13:30) - biospace.com/
KNSA | $17.66 3.31% 3.2% 610K
|
Health Technology
|
| O: -11.69%
H: 13.24%
C: 9.97%
covid-19 trial covid results phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.